Posted on 13/10/2009 in Pharmacy Supplier News GlaxoSmithKline is working with the Wellcome Trust, the East of England Development Agency (EEDA) and the UK government to create a biotechnology science park located at the firm's site in Stevenage.
The new facility will be a world-leading centre for early-stage biotechnology companies aiming to establish a new operating model of open innovation that should strengthen and grow the UK bioscience sector and compete with similar bases abroad.
Andrew Witty, chief executive of GlaxoSmithKline, stated that the centre will "bring together scientists from around the world, providing them with new access to leading research and development facilities. This will foster innovation and accelerate the discovery and development of new medicines".
This news comes after the company revealed last month that its H1N1 virus vaccine has received approval from the European commission ahead of the winter months.
Jean Stephenne, president of GlaxoSmithKline Biologicals, said that the firm is scheduled to ship supplies of the product to European countries this month.
Other news stories from 13/10/2009
Read more in the Zenopa News Archive
How this news is generated
|
